X4 Pharmaceuticals (XFOR) Equity Average (2018 - 2025)

X4 Pharmaceuticals has reported Equity Average for 8 years, with the latest figure at $124.0 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average rose 203.18% year-over-year to $124.0 million; the trailing twelve-month figure through Dec 2025 stood at $124.0 million (up 203.18% YoY), and the FY2025 full-year result was $104.2 million, up 184.57% from the prior year.
• Equity Average for Q4 2025 stood at $124.0 million, up from $32.8 million in the prior quarter.
• The five-year high for Equity Average was $124.0 million in Q4 2025, with the low at $13.5 million in Q2 2025.
• Historically, Equity Average has averaged $58.7 million across 5 years, with a median of $59.5 million in 2023.
• The largest YoY upside for Equity Average was 203.18% in 2025 against a maximum downside of 71.81% in 2025.
• X4 Pharmaceuticals' Equity Average stood at $66.5 million in 2021, then grew by 2.11% to $68.0 million in 2022, then retreated by 12.66% to $59.3 million in 2023, then plunged by 31.11% to $40.9 million in 2024, then jumped by 203.18% to $124.0 million in 2025.
• The last three Equity Average figures came in at $124.0 million (Q4 2025), $32.8 million (Q3 2025), and $13.5 million (Q2 2025), per Business Quant data.